Parkinson's Disease Market Size - Global Industry, Share, Analysis, Trends and Forecast 2022 - 2030

CHAPTER 1. Industry Overview of Parkinson’s Disease Market

1.1. Definition and Scope

1.1.1. Definition of Parkinson’s Disease

1.1.2. Market Segmentation

1.1.3. Years Considered for the Study

1.1.4. Assumptions and Acronyms Used

1.1.4.1. Market Assumptions and Market Forecast

1.1.4.2. Acronyms Used in Global Parkinson’s Disease Market

1.2. Summary

1.2.1. Executive Summary 

1.2.2. Parkinson’s Disease Market By Drug Class

1.2.3. Parkinson’s Disease Market By Distribution Channel

1.2.4. Parkinson’s Disease Market By Patient Care Setting

1.2.5. Parkinson’s Disease Market By Region

CHAPTER 2. Research Approach

2.1. Methodology 

2.1.1. Research Programs

2.1.2. Market Size Estimation

2.1.3. Market Breakdown and Data Triangulation

2.2. Data Source

2.2.1. Secondary Sources

2.2.2. Primary Sources

CHAPTER 3. Market Dynamics And Competition Analysis

3.1. Market Drivers

3.1.1. Driver 1

3.1.2. Driver 2

3.2. Restraints and Challenges

3.2.1. Restraint 1

3.2.2. Restraint 2

3.3. Growth Opportunities

3.3.1. Opportunity 1

3.3.2. Opportunity 2 

3.4. Porter’s Five Forces Analysis

3.4.1. Bargaining Power of Suppliers

3.4.2. Bargaining Power of Buyers

3.4.3. Threat of Substitute

3.4.4. Threat of New Entrants

3.4.5. Degree of Competition

3.5. Market Concentration Ratio and Market Maturity Analysis of Parkinson’s Disease Market

3.5.1. Go To Market Strategy

3.5.1.1. Introduction

3.5.1.2. Growth

3.5.1.3. Maturity

3.5.1.4. Saturation

3.5.1.5. Possible Development

3.6. Technological Roadmap for Parkinson’s Disease Market

3.7. Value Chain Analysis

3.7.1. List of Key Manufacturers 

3.7.2. List of Customers

3.7.3. Level of Integration

3.8. Regulatory Compliance

3.9. Competitive Landscape, 2021

3.9.1. Player Positioning Analysis

3.9.2. Key Strategies Adopted By Leading Players

CHAPTER 4. Parkinson’s Disease Market By Drug Class

4.1. Introduction

4.2. Parkinson’s Disease Revenue By Drug Class

4.2.1. Parkinson’s Disease Revenue (USD Million) and Forecast, By Drug Class, 2018-2030

4.2.2. Carbidopa/Levodopa

4.2.2.1. Carbidopa/Levodopa Market Revenue (USD Million) and Growth Rate (%), 2018-2030

4.2.3. Dopamine Receptor Agonists

4.2.3.1. Dopamine Receptor Agonists Market Revenue (USD Million) and Growth Rate (%), 2018-2030

4.2.4. MAO-Inhibitors

4.2.4.1. MAO-Inhibitors Market Revenue (USD Million) and Growth Rate (%), 2018-2030

4.2.5. COMT-Inhibitors

4.2.5.1. COMT-Inhibitors Market Revenue (USD Million) and Growth Rate (%), 2018-2030

4.2.6. Anticholinergics

4.2.6.1. Anticholinergics Market Revenue (USD Million) and Growth Rate (%), 2018-2030

4.2.7. Other Drugs

4.2.7.1. Other Drugs Market Revenue (USD Million) and Growth Rate (%), 2018-2030

CHAPTER 5. Parkinson’s Disease Market By Distribution Channel

5.1. Introduction

5.2. Parkinson’s Disease Revenue By Distribution Channel

5.2.1. Parkinson’s Disease Revenue (USD Million) and Forecast, By Distribution Channel, 2018-2030

5.2.2. Retailer Pharmacies

5.2.2.1. Retailer Pharmacies Market Revenue (USD Million) and Growth Rate (%), 2018-2030

5.2.3. Online Pharmacies

5.2.3.1. Online Pharmacies Market Revenue (USD Million) and Growth Rate (%), 2018-2030

5.2.4. Hospital Pharmacies

5.2.4.1. Hospital Pharmacies Market Revenue (USD Million) and Growth Rate (%), 2018-2030

CHAPTER 6. Parkinson’s Disease Market By Patient Care Setting

6.1. Introduction

6.2. Parkinson’s Disease Revenue By Patient Care Setting

6.2.1. Parkinson’s Disease Revenue (USD Million) and Forecast, By Patient Care Setting, 2018-2030

6.2.2. Hospitals

6.2.2.1. Hospitals Market Revenue (USD Million) and Growth Rate (%), 2018-2030

6.2.3. Clinics

6.2.3.1. Clinics Market Revenue (USD Million) and Growth Rate (%), 2018-2030

CHAPTER 7. North America Parkinson’s Disease Market By Country 

7.1. North America Parkinson’s Disease Market Overview

7.2. U.S.

7.2.1. U.S. Parkinson’s Disease Revenue (USD Million) and Forecast By Drug Class, 2018-2030

7.2.2. U.S. Parkinson’s Disease Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030

7.2.3. U.S. Parkinson’s Disease Revenue (USD Million) and Forecast By Patient Care Setting, 2018-2030

7.3. Canada

7.3.1. Canada Parkinson’s Disease Revenue (USD Million) and Forecast By Drug Class, 2018-2030

7.3.2. Canada Parkinson’s Disease Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030

7.3.3. Canada Parkinson’s Disease Revenue (USD Million) and Forecast By Patient Care Setting, 2018-2030

7.4. North America PEST Analysis

CHAPTER 8. Europe Parkinson’s Disease Market By Country

8.1. Europe Parkinson’s Disease Market Overview

8.2. U.K.

8.2.1. U.K. Parkinson’s Disease Revenue (USD Million) and Forecast By Drug Class, 2018-2030

8.2.2. U.K. Parkinson’s Disease Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030

8.2.3. U.K. Parkinson’s Disease Revenue (USD Million) and Forecast By Patient Care Setting, 2018-2030

8.3. Germany

8.3.1. Germany Parkinson’s Disease Revenue (USD Million) and Forecast By Drug Class, 2018-2030

8.3.2. Germany Parkinson’s Disease Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030

8.3.3. Germany Parkinson’s Disease Revenue (USD Million) and Forecast By Patient Care Setting, 2018-2030

8.4. France

8.4.1. France Parkinson’s Disease Revenue (USD Million) and Forecast By Drug Class, 2018-2030

8.4.2. France Parkinson’s Disease Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030

8.4.3. France Parkinson’s Disease Revenue (USD Million) and Forecast By Patient Care Setting, 2018-2030

8.5. Spain

8.5.1. Spain Parkinson’s Disease Revenue (USD Million) and Forecast By Drug Class, 2018-2030

8.5.2. Spain Parkinson’s Disease Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030

8.5.3. Spain Parkinson’s Disease Revenue (USD Million) and Forecast By Patient Care Setting, 2018-2030

8.6. Rest of Europe

8.6.1. Rest of Europe Parkinson’s Disease Revenue (USD Million) and Forecast By Drug Class, 2018-2030

8.6.2. Rest of Europe Parkinson’s Disease Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030

8.6.3. Rest of Europe Parkinson’s Disease Revenue (USD Million) and Forecast By Patient Care Setting, 2018-2030

8.7. Europe PEST Analysis

CHAPTER 9. Asia Pacific Parkinson’s Disease Market By Country

9.1. Asia Pacific Parkinson’s Disease Market Overview

9.2. China

9.2.1. China Parkinson’s Disease Revenue (USD Million) and Forecast By Drug Class, 2018-2030

9.2.2. China Parkinson’s Disease Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030

9.2.3. China Parkinson’s Disease Revenue (USD Million) and Forecast By Patient Care Setting, 2018-2030

9.3. Japan

9.3.1. Japan Parkinson’s Disease Revenue (USD Million) and Forecast By Drug Class, 2018-2030

9.3.2. Japan Parkinson’s Disease Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030

9.3.3. Japan Parkinson’s Disease Revenue (USD Million) and Forecast By Patient Care Setting, 2018-2030

9.4. India

9.4.1. India Parkinson’s Disease Revenue (USD Million) and Forecast By Drug Class, 2018-2030

9.4.2. India Parkinson’s Disease Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030

9.4.3. India Parkinson’s Disease Revenue (USD Million) and Forecast By Patient Care Setting, 2018-2030

9.5. Australia

9.5.1. Australia Parkinson’s Disease Revenue (USD Million) and Forecast By Drug Class, 2018-2030

9.5.2. Australia Parkinson’s Disease Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030

9.5.3. Australia Parkinson’s Disease Revenue (USD Million) and Forecast By Patient Care Setting, 2018-2030

9.6. South Korea

9.6.1. South Korea Parkinson’s Disease Revenue (USD Million) and Forecast By Drug Class, 2018-2030

9.6.2. South Korea Parkinson’s Disease Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030

9.6.3. South Korea Parkinson’s Disease Revenue (USD Million) and Forecast By Patient Care Setting, 2018-2030

9.7. Rest of Asia-Pacific

9.7.1. Rest of Asia-Pacific Parkinson’s Disease Revenue (USD Million) and Forecast By Drug Class, 2018-2030

9.7.2. Rest of Asia-Pacific Parkinson’s Disease Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030

9.7.3. Rest of Asia-Pacific Parkinson’s Disease Revenue (USD Million) and Forecast By Patient Care Setting, 2018-2030

9.8. Asia Pacific PEST Analysis

CHAPTER 10. Latin America Parkinson’s Disease Market By Country

10.1. Latin America Parkinson’s Disease Market Overview

10.2. Brazil

10.2.1. Brazil Parkinson’s Disease Revenue (USD Million) and Forecast By Drug Class, 2018-2030

10.2.2. Brazil Parkinson’s Disease Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030

10.2.3. Brazil Parkinson’s Disease Revenue (USD Million) and Forecast By Patient Care Setting, 2018-2030

10.3. Mexico

10.3.1. Mexico Parkinson’s Disease Revenue (USD Million) and Forecast By Drug Class, 2018-2030

10.3.2. Mexico Parkinson’s Disease Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030

10.3.3. Mexico Parkinson’s Disease Revenue (USD Million) and Forecast By Patient Care Setting, 2018-2030

10.4. Rest of Latin America

10.4.1. Rest of Latin America Parkinson’s Disease Revenue (USD Million) and Forecast By Drug Class, 2018-2030

10.4.2. Rest of Latin America Parkinson’s Disease Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030

10.4.3. Rest of Latin America Parkinson’s Disease Revenue (USD Million) and Forecast By Patient Care Setting, 2018-2030

10.5. Latin America PEST Analysis

CHAPTER 11. Middle East & Africa Parkinson’s Disease Market By Country 

11.1. Middle East & Africa Parkinson’s Disease Market Overview

11.2. GCC

11.2.1. GCC Parkinson’s Disease Revenue (USD Million) and Forecast By Drug Class, 2018-2030

11.2.2. GCC Parkinson’s Disease Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030

11.2.3. GCC Parkinson’s Disease Revenue (USD Million) and Forecast By Patient Care Setting, 2018-2030

11.3. South Africa

11.3.1. South Africa Parkinson’s Disease Revenue (USD Million) and Forecast By Drug Class, 2018-2030

11.3.2. South Africa Parkinson’s Disease Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030

11.3.3. South Africa Parkinson’s Disease Revenue (USD Million) and Forecast By Patient Care Setting, 2018-2030

11.4. Rest of Middle East & Africa

11.4.1. Rest of Middle East & Africa Parkinson’s Disease Revenue (USD Million) and Forecast By Drug Class, 2018-2030

11.4.2. Rest of Middle East & Africa Parkinson’s Disease Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030

11.4.3. Rest of Middle East & Africa Parkinson’s Disease Revenue (USD Million) and Forecast By Patient Care Setting, 2018-2030

11.5. Middle East & Africa PEST Analysis

CHAPTER 12. Player Analysis Of Parkinson’s Disease Market

12.1. Parkinson’s Disease Market Company Share Analysis

12.2. Competition Matrix

12.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment

12.2.2. New Product Launches and Product Enhancements

12.2.3. Mergers And Acquisition In Global Parkinson’s Disease Market

12.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements

CHAPTER 13. Company Profile

13.1. Teva

13.1.1. Company Snapshot

13.1.2. Business Overview

13.1.3. Financial Overview

13.1.3.1. Revenue (USD Million), 2021

13.1.3.2. Teva 2021 Parkinson’s Disease Business Regional Distribution

13.1.4. Product /Service and Specification

13.1.5. Recent Developments & Business Strategy

13.2. Novartis AG

13.3. GSK

13.4. AbbVie

13.5. Merck

13.6. Boehringer Ingelheim

13.7. Impax Laboratories

13.8. Lundbeck

13.9. UCB

13.10. Valeant Pharmaceuticals

13.11. Acadia